CD274 and non-small cell lung carcinoma: This meta-analysis reinforces the clinical value of PD-1/PD-L1 inhibitors combined with nab-paclitaxel-platinum chemotherapy in NSCLC, albeit with increased risks of thrombocytopenia and immune-related toxicities.